Clinical trial
Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients…
NCT00233558 · Abbott, Industry · Terminated
Key facts
| NCT number | NCT00233558 |
|---|---|
| Title | Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis |
| Official title | Multicentre, Randomised, Open Label Study Comparing a "Scheduled Steroid Reduction Strategy" Versus a Free Steroid Reduction Strategy (Physician's Usual Practice for Reducing Steroids) in Patients With Active RA Treated With Humira 40 mg Eow + MTX During 9 Months |
| Lead sponsor | Abbott, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | adalimumab (up to 9 months exposure), methotrexate |
| Enrollment | 160 |
| Start date | Jun 1, 2005 |
| First posted | Oct 6, 2005 |
| Last update posted | Apr 24, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: